The Burden of Invasive Fungal Disease Following Chimeric Antigen Receptor T-Cell Therapy and Strategies for Prevention.

Details

Serval ID
serval:BIB_ED0EE5EE130E
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
The Burden of Invasive Fungal Disease Following Chimeric Antigen Receptor T-Cell Therapy and Strategies for Prevention.
Journal
Open forum infectious diseases
Author(s)
Little J.S., Kampouri E., Friedman D.Z., McCarty T., Thompson G.R., Kontoyiannis D.P., Vazquez J., Baddley J.W., Hammond S.P.
ISSN
2328-8957 (Print)
ISSN-L
2328-8957
Publication state
Published
Issued date
06/2024
Peer-reviewed
Oui
Volume
11
Number
6
Pages
ofae133
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Abstract
Chimeric antigen receptor (CAR) T-cell therapy is a novel immunotherapy approved for the treatment of hematologic malignancies. This therapy leads to a variety of immunologic deficits that could place patients at risk for invasive fungal disease (IFD). Studies assessing IFD in this setting are limited by inconsistent definitions and heterogeneity in prophylaxis use, although the incidence of IFD after CAR T-cell therapy, particularly for lymphoma and myeloma, appears to be low. This review evaluates the incidence of IFD after CAR T-cell therapy, and discusses optimal approaches to prevention, highlighting areas that require further study as well as future applications of cellular therapy that may impact IFD risk. As the use of CAR T-cell therapy continues to expand for hematologic malignancies, solid tumors, and most recently to include non-oncologic diseases, understanding the risk for IFD in this uniquely immunosuppressed population is imperative to prevent morbidity and mortality.
Keywords
CAR T-cell therapy, antifungal prophylaxis, antifungal stewardship, immunotherapy, invasive fungal disease
Pubmed
Open Access
Yes
Create date
20/06/2024 16:19
Last modification date
21/06/2024 7:07
Usage data